Core Viewpoint - LY104 injection, developed by a collaboration between Ocean University of China, Qingdao Marine Biomedical Research Institute, and Qingdao Haiji Biomedical Co., Ltd., has successfully passed the technical review by the National Medical Products Administration and received the Clinical Trial Approval Notification [1] Group 1: Drug Development - LY104 is the first Class 1 marine small molecule drug approved for clinical trials under the "Blue Drug Library" development plan [1] - It is the third marine drug to be approved for clinical trials, following BG136 and LY102, and is intended for the treatment of chronic obstructive pulmonary disease (COPD) [1] Group 2: Research and Innovation - The LY104 project was led by Professor Hao Jiejie from the School of Medicine at Ocean University of China, who utilized an innovative approach that combines cutting-edge technology with interdisciplinary collaboration [1] - The project team effectively integrated artificial intelligence and model animal screening technology to identify a new class of active structured compounds from marine bryozoans [1] - The "Smart Blue Drug" platform was employed for systematic structural optimization, synthesis process innovation, drug-like property evaluation, and pharmacological efficacy verification, leading to the development of the LY104 molecule [1]